Skip to main content

Advertisement

SpringerLink
Log in

Prophylactic treatment of migraine with and without aura with acetyl-dl-leucine: a case series

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808

    Article  Google Scholar 

  2. Bremova T, Malinova V, Amraoui Y, Mengel E, Reinke J, Kolnikova M, Strupp M (2015) Acetyl-dl-leucine in Niemann-Pick type C: a case series. Neurology 85:1368–1375

    Article  CAS  Google Scholar 

  3. Brennan KC, Pietrobon D (2018) A systems neuroscience approach to migraine. Neuron 97:1004–1021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478–488

    Article  PubMed  Google Scholar 

  5. Lempert T, Olesen J, Furman J, Waterston J, Seemungal B, Carey J, Bisdorff A, Versino M, Evers S, Newman-Toker D (2012) Vestibular migraine: diagnostic criteria. J Vestib Res 22:167–172

    PubMed  Google Scholar 

  6. Strupp M, Teufel J, Habs M, Feuerecker R, Muth C, van de Warrenburg B, Klopstock T, Feil K (2013) Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series. J Neurol 260:2556–2561

    Article  Google Scholar 

  7. Vibert N, Vidal PP (2001) In vitro effects of acetyl-dl-leucine (tanganil) on central vestibular neurons and vestibulo-ocular networks of the guinea-pig. Eur J Neurosci 13:735–748

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Katie Göttlinger for copy editing this manuscript. This work was supported by the German Ministry of Education and Research (BMBF), Grant no. 01EO0901 to the German Center for Vertigo and Balance Disorders (IFBLMU).

Author information

Authors and Affiliations

  1. Department of Neurology, Ludwig Maximilians University, Munich, Campus Grosshadern, Marchioninistr. 15, 81377, Munich, Germany

    Michael Strupp, Katharina Feil & Andreas Straube

  2. Reliatec GmbH, Garching, Germany

    Otmar Bayer

  3. Ludwig Maximilians University, Munich, Munich, Germany

    Otmar Bayer

Authors
  1. Michael Strupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otmar Bayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katharina Feil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andreas Straube
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MS: conception of the study, acquisition and interpretation of the data, drafting the manuscript. OB: statistical analysis, interpretation of the data, and revising the manuscript for content. KF: conception of the study and recruitment of patients. AS: acquisition and interpretation of the data, as well as drafting the manuscript.

Corresponding author

Correspondence to Michael Strupp.

Ethics declarations

Conflicts of interest

M. Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Bayer, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, and UCB. He is a shareholder of IntraBio. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion. O. Bayer and K. Feil report no relevant conflicts of interest/financial disclosures. A. Straube has received speaker’s honoraria from Allergan, Novartis, TEVA and Recordati. He received honoraria for adboard participation from Allergan, Novartis, TEVA, Eli Lilly, electroCore.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

All patients gave their informed consent for the compassionate use of acetyl-dl-leucine.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strupp, M., Bayer, O., Feil, K. et al. Prophylactic treatment of migraine with and without aura with acetyl-dl-leucine: a case series. J Neurol 266, 525–529 (2019). https://doi.org/10.1007/s00415-018-9155-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-018-9155-6

Search

Navigation